The potential of targeting adenosine 5′-monophosphate-activated protein kinase to treat peripheral artery disease: Evidence from preclinical mouse models
Callan D. Wesley, Shivshankar Thanigaimani, Jonathan S. Oakhill, Jonathan Golledge. The potential of targeting adenosine 5′-monophosphate-activated protein kinase to treat peripheral artery disease: Evidence from preclinical mouse models. // Vascular Pharmacology. – 2026. – DOI: 10.1016/j.vph.2026.107708. – URL: https://doi.org/10.1016/j.vph.2026.107708
Callan D. Wesley, Shivshankar Thanigaimani, Jonathan S. Oakhill, & Jonathan Golledge (2026). The potential of targeting adenosine 5′-monophosphate-activated protein kinase to treat peripheral artery disease: Evidence from preclinical mouse models. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2026.107708
Callan D. Wesley, et al. “The potential of targeting adenosine 5′-monophosphate-activated protein kinase to treat peripheral artery disease: Evidence from preclinical mouse models.” Vascular Pharmacology, 2026. doi:10.1016/j.vph.2026.107708.
@article{Wesley2026,
title = {The potential of targeting adenosine 5′-monophosphate-activated protein kinase to treat peripheral artery disease: Evidence from preclinical mouse models},
author = {Wesley, Callan D. and Thanigaimani, Shivshankar and Oakhill, Jonathan S. and Golledge, Jonathan},
journal = {Vascular Pharmacology},
year = {2026},
doi = {10.1016/j.vph.2026.107708},
url = {https://doi.org/10.1016/j.vph.2026.107708}
}